Phase 2 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with advanced (unable to be surgically removed) or metastatic melanoma (skin cancer that has spread), confirmed by a lab test, whose cancer has come back or gotten worse after at least one previous treatment — note that eye (uveal) melanoma does not qualify
- People aged 18 or older who are male, or female and neither pregnant nor breastfeeding
- People whose general health and ability to carry out daily activities meets a certain standard (rated 0 or 1 on a medical scale, meaning fully active or able to do light work — confirm with trial site)
- People who have at least one measurable area of cancer that can be tracked on scans
- People expected to live at least 3 months, based on the treating doctor's assessment
- People who are able to swallow tablets or capsules and are willing to keep a daily record of taking the study medication
- People who have adequate blood cell counts and bone marrow function
- People who have adequate kidney and liver function
- People who are willing and able to sign a consent form agreeing to take part
- People who agree to provide a stored or freshly collected tissue sample for research
Who may not be able to join:
- People who have a history of another type of cancer
- People who have cancer that has spread to the brain and is causing symptoms requiring more than 10 mg per day of prednisolone (a steroid medication)
- People with serious heart or blood vessel disease
- People with a known active hepatitis B, hepatitis C, or HIV/AIDS-related illness
- People who have received a live vaccine within the past 30 days before joining
- People with a history of active autoimmune conditions (where the immune system attacks the body), or who are currently taking medication that suppresses the immune system
- People who still have significant side effects from previous radiation or chemotherapy that have not improved to a mild level
- People who are currently receiving other cancer treatments, other experimental treatments, or certain medications that strongly affect how the body processes drugs (confirm with trial site)
- People who have previously been treated with a specific type of drug called an HPK1 inhibitor
- People who have a known allergy to any ingredient in the study drug, or any other allergy the doctor considers would make participation unsafe
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hui Ouyang, Dr., VP
Phone: 8617728075858
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective response rate (ORR); Recommended phase 2 dose (RP2D)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.